Also listed under Prostatic Diseases
ClinicalTrials.gov term: Prostatic Neoplasms
150 trials changed in the last 30 days: 2 stopped, 76 with notable changes, 72 with minor changes only.
Trial terminated
Also in this update: Results posted: Oct 19, 2026; Study completion date changed from estimate of Apr 14, 2027 to Apr 14, 2026
University of WashingtonPhase 2 NCT05960578 Registry history of NCT05960578 on ClinicalTrials.gov (opens the registry)
Trial terminated
Also in this update: Primary completion date changed from estimate of Jun 2027 to Aug 4, 2026; Final enrollment: 28 participants (planned 48)
GCS Ramsay Santé pour l'Enseignement et la RechercheNot applicable NCT05745844 Registry history of NCT05745844 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Nov 30, 2026 to May 31, 2027
Novartis PharmaceuticalsNot specified NCT07677267 Registry history of NCT07677267 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Nov 30, 2026 to May 31, 2027
Novartis PharmaceuticalsNot specified NCT07677254 Registry history of NCT07677254 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from May 2026 to Dec 2026
Bivision Pharmaceuticals, Inc.Phase 1/2 NCT06139575 Registry history of NCT06139575 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Apr 1, 2031 to Oct 1, 2031
Merck Sharp & Dohme LLCPhase 1/2 NCT06863272 Registry history of NCT06863272 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Nov 2, 2026 to Jun 1, 2027
National Cancer Institute (NCI)Phase 2 NCT05691465 Registry history of NCT05691465 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Mar 31, 2026 to Nov 30, 2026
Also in this update: Enrollment closed, study ongoing; Study completion pushed from Oct 31, 2026 to May 30, 2027
Stratagen Bio, Inc.Not applicable NCT06985238 Registry history of NCT06985238 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Apr 1, 2028 to Apr 1, 2033
Also in this update: Study completion pushed from Oct 1, 2031 to Oct 1, 2036
SWOG Cancer Research NetworkPhase 3 NCT03678025 Registry history of NCT03678025 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Dec 31, 2026 to Apr 20, 2030
Also in this update: Enrollment increased: 470 → 540 participants; Study completion pushed from Mar 21, 2028 to Jul 22, 2030
SystImmune Inc.Phase 1 NCT05983432 Registry history of NCT05983432 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from May 25, 2027 to May 29, 2028
City of Hope Medical CenterNot applicable NCT05519878 Registry history of NCT05519878 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Dec 1, 2027 to Dec 1, 2028
Also in this update: Trial sites expanded: 5 → 13 locations; Study completion pushed from Dec 31, 2027 to Dec 31, 2028
Palette Life Sciences, Inc.Not applicable NCT06496256 Registry history of NCT06496256 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jan 31, 2026 to Dec 31, 2027
Also in this update: Trial sites expanded: 12 → 19 locations; Study completion pushed from Oct 31, 2027 to Feb 28, 2029
Fundacion OncosurPhase 2 NCT06582628 Registry history of NCT06582628 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Dec 31, 2026 to Dec 31, 2027
National Cancer Institute (NCI)Phase 2 NCT02465060 Registry history of NCT02465060 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Aug 31, 2026 to Aug 31, 2028
Also in this update: Study completion pushed from Aug 31, 2029 to Aug 31, 2031
Mayo ClinicEarly Phase 1 NCT05045066 Registry history of NCT05045066 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Dec 31, 2026 to Dec 31, 2030
Uppsala UniversityNot specified NCT06446401 Registry history of NCT06446401 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Sep 8, 2026 to Sep 8, 2027
Memorial Sloan Kettering Cancer CenterNot specified NCT05540782 Registry history of NCT05540782 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Aug 30, 2026 to Apr 30, 2027
Also in this update: Study completion pushed from Aug 30, 2031 to Apr 30, 2032
Mayo ClinicNot applicable NCT06325046 Registry history of NCT06325046 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jan 21, 2027 to Jul 31, 2029
Also in this update: Study completion pushed from Jan 21, 2027 to Jul 31, 2032
National Institutes of Health Clinical Center (CC)Not applicable NCT02759744 Registry history of NCT02759744 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Oct 11, 2026 to Oct 11, 2028
M.D. Anderson Cancer CenterPhase 2 NCT03821792 Registry history of NCT03821792 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Final enrollment: 378 participants (planned 464)
VA Office of Research and DevelopmentPhase 2/3 NCT04787744 Registry history of NCT04787744 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Atridia Pty Ltd.Phase 1 NCT06830850 Registry history of NCT06830850 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Jan 1, 2026 to Jun 11, 2026
HTA Co., Ltd.Phase 3 NCT06754085 Registry history of NCT06754085 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Jan 7, 2026 to Aug 7, 2025
Medtechtomarket Consulting LtdNot specified NCT06554587 Registry history of NCT06554587 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Study completion date changed from estimate of Oct 1, 2026 to Sep 1, 2026; Final enrollment: 1334 participants (planned 1020)
Dana-Farber Cancer InstituteNot applicable NCT05225428 Registry history of NCT05225428 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Study completion date changed from estimate of Jan 2026 to May 2, 2024
Mark SteinPhase 1/2 NCT03689699 Registry history of NCT03689699 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Primary completion pushed from Jul 2026 to Nov 2026; Study completion pushed from Jan 2027 to Nov 2027
University of UtahPhase 2 NCT05168618 Registry history of NCT05168618 on ClinicalTrials.gov (opens the registry)
Trial status changed: Not Yet Recruiting → Active, Not Recruiting
PfizerNot specified NCT07779590 Registry history of NCT07779590 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Study completion pushed from May 29, 2026 to Dec 31, 2026; Primary completion date changed from estimate of Mar 30, 2026 to Aug 31, 2026
AIQ SolutionsNot applicable NCT06815354 Registry history of NCT06815354 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Dec 31, 2026 to Jun 30, 2026; Final enrollment: 477 participants (planned 700)
BayerNot specified NCT06874114 Registry history of NCT06874114 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Trial sites reduced: 65 → 39 locations; Final enrollment: 159 participants (planned 300)
AstraZenecaNot specified NCT06031805 Registry history of NCT06031805 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Study completion date changed from estimate of Sep 30, 2026 to Jun 30, 2026; Final enrollment: 506 participants (planned 1116)
Medstar Health Research InstituteNot applicable NCT05301114 Registry history of NCT05301114 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Dec 30, 2027 to Feb 23, 2026
Mayo ClinicNot applicable NCT06037863 Registry history of NCT06037863 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Feb 13, 2032 to Mar 15, 2032
Also in this update: Study completion pushed from Sep 4, 2035 to Oct 4, 2035
Novartis PharmaceuticalsPhase 2 NCT06991556 Registry history of NCT06991556 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Final enrollment: 230 participants (planned 102)
Ankara Etlik City HospitalNot specified NCT07181122 Registry history of NCT07181122 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
University of ChicagoNot applicable NCT05608694 Registry history of NCT05608694 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Final enrollment: 11 participants (planned 30)
University of FloridaNot applicable NCT06465966 Registry history of NCT06465966 on ClinicalTrials.gov (opens the registry)
Trial completed
Icahn School of Medicine at Mount SinaiNot applicable NCT07141121 Registry history of NCT07141121 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Apr 20, 2027 to Aug 2027
Also in this update: Study completion pushed from Apr 20, 2027 to Oct 2031
Convergent TherapeuticsPhase 2 NCT06549465 Registry history of NCT06549465 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Jul 11, 2028 to Aug 17, 2028
Janssen Research & Development, LLCPhase 1/2 NCT06800313 Registry history of NCT06800313 on ClinicalTrials.gov (opens the registry)
Enrollment increased: 285 → 330 participants
ModeX Therapeutics, An OPKO Health CompanyPhase 1/2 NCT06239194 Registry history of NCT06239194 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Dec 2026 to Oct 2, 2026
Stephen FreedlandPhase 2 NCT03824652 Registry history of NCT03824652 on ClinicalTrials.gov (opens the registry)
Completed without a posted recruiting period
Also in this update: Primary completion date changed from estimate of Jun 30, 2026 to Aug 29, 2026
Zhu YinjiePhase 2 NCT07415135 Registry history of NCT07415135 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Jul 2026 to Apr 10, 2025
Mark SteinPhase 1 NCT05077098 Registry history of NCT05077098 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Aug 2027 to Dec 2027
Also in this update: Study completion pushed from Aug 2031 to Dec 2031
University of Michigan Rogel Cancer CenterPhase 1 NCT07682649 Registry history of NCT07682649 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 132 → 151 locations
AstraZenecaPhase 3 NCT07611110 Registry history of NCT07611110 on ClinicalTrials.gov (opens the registry)
Completed without a posted recruiting period
Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoNot applicable NCT07234097 Registry history of NCT07234097 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Oct 1, 2026 to Aug 10, 2026
City of Hope Medical CenterNot applicable NCT03035500 Registry history of NCT03035500 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Primary completion pushed from Aug 1, 2026 to Nov 10, 2026; Study completion pushed from Aug 1, 2026 to Jan 1, 2027
Vivek NarayanNot applicable NCT06064149 Registry history of NCT06064149 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 33 → 52 locations
BioNTech SEPhase 3 NCT07365995 Registry history of NCT07365995 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 298 → 303 locations
Merck Sharp & Dohme LLCPhase 3 NCT06925737 Registry history of NCT06925737 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 100 → 106 locations
And 1 more change in the last 30 days
Novartis PharmaceuticalsPhase 3 NCT06855277 Registry history of NCT06855277 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 307 → 319 locations
And 1 more change in the last 30 days
PfizerPhase 3 NCT07028853 Registry history of NCT07028853 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Dec 18, 2026 to May 15, 2027
Mayo ClinicPhase 2 NCT07285044 Registry history of NCT07285044 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from May 1, 2034 to Oct 1, 2034
University Health Network, TorontoPhase 2 NCT07515651 Registry history of NCT07515651 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from May 27, 2028 to Oct 1, 2028
Also in this update: Study completion pushed from May 27, 2030 to Oct 1, 2030
University Health Network, TorontoPhase 2 NCT06836726 Registry history of NCT06836726 on ClinicalTrials.gov (opens the registry)
Enrollment increased: 50 → 60 participants
Also in this update: Start date pushed from Oct 5, 2026 to Oct 15, 2026
BayerNot specified NCT07806591 Registry history of NCT07806591 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 7 → 12 locations
ORIC PharmaceuticalsPhase 3 NCT07723248 Registry history of NCT07723248 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 212 → 227 locations
CelgenePhase 3 NCT06764485 Registry history of NCT06764485 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 152 → 158 locations
Also in this update: Study completion pushed from Jul 20, 2029 to Jun 7, 2030
Janssen Research & Development, LLCPhase 3 NCT07225946 Registry history of NCT07225946 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 236 → 233 locations
PfizerPhase 3 NCT06629779 Registry history of NCT06629779 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 81 → 93 locations
Novartis PharmaceuticalsPhase 2/3 NCT06780670 Registry history of NCT06780670 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 91 → 94 locations
Daiichi SankyoPhase 2 NCT06172478 Registry history of NCT06172478 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 13 → 22 locations
Astellas Pharma Global Development, Inc.Phase 1 NCT05997615 Registry history of NCT05997615 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 8 → 25 locations
Olema Pharmaceuticals, Inc.Phase 1 NCT06784193 Registry history of NCT06784193 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 9 → 13 locations
Acerand Therapeutics (Hong Kong) LimitedPhase 1 NCT06801236 Registry history of NCT06801236 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 5 → 9 locations
Novartis PharmaceuticalsPhase 1 NCT07570979 Registry history of NCT07570979 on ClinicalTrials.gov (opens the registry)
Final enrollment: 15 participants (planned 10)
And 2 more changes in the last 30 days
Antelope Surgical Solutions, IncPhase 1/2 NCT06906471 Registry history of NCT06906471 on ClinicalTrials.gov (opens the registry)
Enrollment increased: 172 → 210 participants
Mälardalen UniversityNot applicable NCT06719206 Registry history of NCT06719206 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 129 → 138 locations
Alliance for Clinical Trials in OncologyPhase 3 NCT07200830 Registry history of NCT07200830 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 210 → 213 locations
Alliance for Clinical Trials in OncologyPhase 3 NCT06931340 Registry history of NCT06931340 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Feb 27, 2027 to Dec 31, 2027
Janssen Research & Development, LLCPhase 3 NCT03748641 Registry history of NCT03748641 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 18 → 23 locations
Alliance for Clinical Trials in OncologyNot applicable NCT07059884 Registry history of NCT07059884 on ClinicalTrials.gov (opens the registry)
Interventions modified
PfizerPhase 1 NCT03460977 Registry history of NCT03460977 on ClinicalTrials.gov (opens the registry)
Interventions modified
ExelixisPhase 1 NCT05176483 Registry history of NCT05176483 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Oct 30, 2028 to Dec 29, 2028
Janssen Research & Development, LLCPhase 1 NCT06788509 Registry history of NCT06788509 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Oct 27, 2026 to Mar 10, 2030
NRG OncologyPhase 2 NCT03371719 Registry history of NCT03371719 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Aug 17, 2026 to Aug 17, 2027
Medical College of WisconsinNot applicable NCT02177292 Registry history of NCT02177292 on ClinicalTrials.gov (opens the registry)
Start date pushed from Sep 2026 to Oct 2026
University of Wisconsin, MadisonEarly Phase 1 NCT07609225 Registry history of NCT07609225 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Jun 2026 to Feb 2028
Also in this update: Primary completion date changed from estimate of Jun 2026 to Aug 30, 2025
University College CorkNot applicable NCT05946993 Registry history of NCT05946993 on ClinicalTrials.gov (opens the registry)
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Epigenetix, Inc.Phase 1 NCT05488548 Registry history of NCT05488548 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Aug 2023); last known: Not Yet Recruiting
Power Life Sciences Inc.Not specified NCT06009549 Registry history of NCT06009549 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Dec 2023); last known: Not Yet Recruiting
Power Life Sciences Inc.Not specified NCT05411354 Registry history of NCT05411354 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Active, Not Recruiting
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSPhase 2 NCT03230734 Registry history of NCT03230734 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
First Affiliated Hospital of Fujian Medical UniversityEarly Phase 1 NCT06612580 Registry history of NCT06612580 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Jan 2024); last known: Active, Not Recruiting
National University Hospital, SingaporePhase 1 NCT06193993 Registry history of NCT06193993 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Ankara UniversityNot specified NCT06612034 Registry history of NCT06612034 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Consorci Sanitari de TerrassaNot specified NCT06184464 Registry history of NCT06184464 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
European Institute of OncologyNot specified NCT06071195 Registry history of NCT06071195 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Hospices Civils de LyonNot applicable NCT05714774 Registry history of NCT05714774 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Karolinska InstitutetNot applicable NCT05100121 Registry history of NCT05100121 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Active, Not Recruiting
University College, LondonNot applicable NCT04571840 Registry history of NCT04571840 on ClinicalTrials.gov (opens the registry)
Changed
Registry verification sweep
Changed
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-10-19 | NCT07879820 PSMA-Guided Surgery and Tissue-Resident T-Cell Profiling in Node-Positive Prostate Cancer | Niguarda Hospital new | |
| 2026-10-16 | NCT07878663 Developing and Validating Health Education Module for Prostate Cancer Prevention Behavior… | Universiti Sains Malaysia new | |
| 2026-10-15 | NCT07875192 Hugo™ Robotic Assisted Surgery (RAS) System in Prostatectomy Patients Treated in an ASC… | Central Ohio Urology Group new | |
| 2026-10-13 | NCT07869888 A Study of QLS2401 Injection in Participants With Advanced Prostate Cancer | Shanghai Qilu Pharmaceutical Research and Development Center LTD new | Phase 1 |
| 2026-10-13 | NCT07870096 ITR-251 in Patients With Advanced Solid Tumors | ITERIA BIOPHARMA, S.L. new | Phase 1 |
| 2026-10-13 | NCT07871435 GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic… | GI Innovation, Inc. new | Phase 1/2 |
| 2026-10-08 | NCT07866300 A Study of KMV002 in Patients With mAPMR Prostate Cancer | Chimivac INC new | Phase 1 |
| 2026-10-07 | NCT07862582 RYZ711 Diagnostic Platform Study | RayzeBio, Inc. new | Phase 1/2 |
| 2026-09-28 | NCT07844304 CascadeDiagnose Prostate MRI | First Affiliated Hospital of Guangxi Medical University new | |
| 2026-09-24 | NCT07838753 A Study Testing if Patients With Advanced Prostate Cancer Who Are Responding Well to… | Kokilaben Dheerubhai Ambani Hospital and Research new | Phase 2 |
| Early Phase 1 | 44 | |
| Phase 1 | 205 | |
| Phase 1/2 | 160 | |
| Phase 2 | 420 | |
| Phase 2/3 | 32 | |
| Phase 3 | 169 | |
| Phase 4 | 30 |
M.D. Anderson Cancer Center (43) · National Cancer Institute (NCI) (42) · Memorial Sloan Kettering Cancer Center (41) · Jonsson Comprehensive Cancer Center (32) · Novartis Pharmaceuticals (32) · AstraZeneca (27) · Mayo Clinic (27) · University Health Network, Toronto (27) · City of Hope Medical Center (22) · Janssen Research & Development, LLC (20)